following a resubmission:

collagenase clostridium histolyticum (Xiapex®) is accepted for restricted use within NHS Scotland.

Indication under review: treatment of Dupuytren’s contracture in adult patients with a palpable cord.

SMC restriction: restricted to use as an alternative to limited fasciectomy in adult patients with Dupuytren’s contracture of moderate severity (as defined by the British Society for Surgery of the Hand (BSSH), with a palpable cord and up to two affected joints per hand, who are suitable for limited fasciectomy, but for whom percutaneous needle fasciotomy is not considered a suitable treatment option.

Collagenase clostridium histolyticum compared to placebo significantly reduces primary joint contracture in adults with Dupuytren’s contracture and palpable cord.

The cost-effectiveness of collagenase clostridium histolyticum relative to percutaneous needle fasciotomy was not demonstrated.

Medicine details

Medicine name:
collagenase (Xiapex)
treatment of Dupuytren' s contracture in adult patients with a palpable cord.
Pharmaceutical company
Pfizer Ltd
BNF chapter
Musculoskeletal and joint diseases
Submission type
Date advice published:
14 May 2012